UBS Adjusts Coherus BioSciences Rating and Target Price

Summary

UBS has maintained its rating for Coherus BioSciences as neutral, but has adjusted its target price from $1.50 to $1.05. Coherus BioSciences is a biopharmaceutical company focused on the research, development, and commercialization of FDA-approved oncology products, including Loqtorzi and Udenyca. The company also plans to launch the Humira biosimilar Yusimry in the U.S. in 2023.Stock Star

Impact Analysis

Level: Company. This event pertains specifically to Coherus BioSciences, affecting its stock performance and investor perception. First-Order Effects: The adjustment in target price by UBS reflects a reassessment of Coherus BioSciences’ financial outlook and market conditions, which may lead to a decrease in investor confidence and potentially impact its stock price negatively. Second-Order Effects: This change could influence the broader sentiment towards biopharmaceutical companies’ stock performance, particularly those involved in oncology products and biosimilars. Investment Opportunities/Risks: Investors may consider the reduced target price as a signal to reassess their positions in Coherus BioSciences, potentially adjusting their portfolio to account for decreased expected returns. There’s also a risk of negative sentiment spilling over to similar companies in the sector.Stock Star